Personalized cancer vaccine epitope selection
AssigneeModernaTX, Inc.
InventorsShan Zhong, Benjamin Breton, Iain Mcfadyen, Kristen Hopson, Vincent Luczkow, Maija Garnaas
Life of this patent
Estimating the term…
Abstract
The disclosure relates to optimized cancer vaccines, as well as methods of making the vaccines, using the vaccines, and compositions comprising the vaccines. The cancer vaccines comprise personalized cancer antigens or portions of cancer hotspot antigens. Additionally, the disclosure relates to a computerized system for selecting nucleic acids to include in an optimized cancer vaccine.
Claims91
A nucleic acid cancer vaccine, comprising:
- one or more nucleic acids each having one or more open reading frames encoding 3-130 peptide epitopes,
- wherein each of the peptide epitopes are portions of personalized cancer antigens or portions of cancer hotspot antigens, and
- wherein at least two of the peptide epitopes have different lengths.
A nucleic acid cancer vaccine, comprising:
- one or more nucleic acids each having one or more open reading frames encoding 5-130 peptide epitopes,
- wherein each of the peptide epitopes are portions of personalized cancer antigens or portions of cancer hotspot antigens, and
- wherein each peptide epitope has an equal length.
A method of making a cancer vaccine comprising:
- a) identifying between 1-34 cancer hotspots;
- b) identifying between 5-130 personalized cancer antigens for a patient;
- c) determining the anti-tumor efficacy of at least two peptide epitopes for each of the 5-130 personalized cancer antigens;
- and
- d) preparing a cancer vaccine in which the total anti-cancer efficacy of the cancer vaccine is maximized for a given total length of the cancer vaccine and wherein the vaccine comprises portions of 1-34 cancer hotspot neoantigens.
A method for treating a patient having cancer, comprising:
- a) analyzing a sample derived from a patient in order to identify one or more personalized cancer antigens;
- b) determining the anti-tumor efficacy of at least two peptide epitopes for each of the identified personalized cancer antigens;
- c) preparing a cancer vaccine in which the total anti-cancer efficacy of the cancer vaccine is maximized for a given total length of the cancer vaccine, wherein the cancer vaccine further comprises portions of 1-34 cancer hotspot antigens;
- and
- d) administering the cancer vaccine to the patient.
A computerized system for selecting nucleic acids to include in a nucleic acid cancer vaccine having a maximum length, the system comprising:
- a communication interface configured to receive a plurality of sequences of nucleic acids encoding a plurality of peptide epitopes, wherein each of the peptide epitopes are portions of personalized cancer antigens;
- and
- at least one computer processor programmed to:
- for each of the plurality of peptide epitopes, calculate a score for each of a plurality of nucleic acids in the peptide, each of which includes at least one of the one or more peptide epitopes, wherein at least two of the nucleic acid sequences have different lengths;
- and
- ranking based on the calculated scores, the plurality of nucleic acid sequences in the plurality of peptides;
- and
- selecting based on the ranking and the maximum length of the vaccine, nucleic acid sequences for inclusion in the vaccine.
Dependencies are inferred from the claim text.